Drug intelligence / Profile preview

NUFIRI + EGFR inhibitor

Development stage: Preclinical
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

NUFIRI + EGFR inhibitor is a combination therapy that includes NUC-3373 (a component of NUFIRI) with leucovorin, irinotecan, and an EGFR inhibitor. EGFR inhibitors are targeted agents that bind to the epidermal growth factor receptor (EGFR) to slow down or stop cell growth in cancers where EGFR is overexpressed or mutated. This combination is likely being investigated for treatment of various cancers.

Targets

TOP1 (DNA Topoisomerase I)

Beyond the preview

Go deeper on NUFIRI + EGFR inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUFIRI + EGFR inhibitor.

Explore the full profile